Bio Path Holdings Stock Net Income
| BPTH Stock | USD 0.80 0.02 2.44% |
Bio Path Holdings fundamentals help investors to digest information that contributes to Bio Path's financial success or failures. It also enables traders to predict the movement of Bio Stock. The fundamental analysis module provides a way to measure Bio Path's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bio Path stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -16.1 M | -15.3 M | |
| Net Loss | -16.7 M | -15.8 M | |
| Net Loss | -9.4 M | -9.9 M | |
| Net Loss | (33.64) | (35.32) | |
| Net Income Per E B T | 1.15 | 1.10 |
Bio | Net Income |
Bio Path Holdings Company Net Income Analysis
Bio Path's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Bio Path Net Income | (16.08 M) |
Most of Bio Path's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Path Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bio Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Bio Path is extremely important. It helps to project a fair market value of Bio Stock properly, considering its historical fundamentals such as Net Income. Since Bio Path's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bio Path's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bio Path's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Bio Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Bio Path Holdings reported net income of (16.08 Million). This is 104.71% lower than that of the Biotechnology sector and 122.95% lower than that of the Health Care industry. The net income for all United States stocks is 102.82% higher than that of the company.
Bio Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Path's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Path could also be used in its relative valuation, which is a method of valuing Bio Path by comparing valuation metrics of similar companies.Bio Path is currently under evaluation in net income category among its peers.
Bio Path Institutional Holders
Institutional Holdings refers to the ownership stake in Bio Path that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bio Path's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bio Path's value.| Shares | Global Retirement Partners, Llc. | 2024-09-30 | 4.0 | Hanson Mcclain Inc | 2024-09-30 | 1.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Hrt Financial Llc | 2024-06-30 | 14.1 K | Geode Capital Management, Llc | 2024-09-30 | 13.6 K | Vanguard Group Inc | 2024-09-30 | 13.5 K | Citadel Advisors Llc | 2024-09-30 | 10.9 K | Tower Research Capital Llc | 2024-06-30 | 3.7 K | Blackrock Inc | 2024-06-30 | 2.4 K | Ubs Group Ag | 2024-06-30 | 859 |
Bio Fundamentals
| Return On Equity | -3.66 | ||||
| Return On Asset | -1.4 | ||||
| Current Valuation | 3 M | ||||
| Shares Outstanding | 4.31 M | ||||
| Shares Owned By Institutions | 1.08 % | ||||
| Number Of Shares Shorted | 77.76 K | ||||
| Price To Earning | (6.21) X | ||||
| Price To Book | 2.33 X | ||||
| EBITDA | (15.76 M) | ||||
| Net Income | (16.08 M) | ||||
| Cash And Equivalents | 17.02 M | ||||
| Cash Per Share | 2.38 X | ||||
| Total Debt | 113 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.57 X | ||||
| Book Value Per Share | 0.71 X | ||||
| Cash Flow From Operations | (11.54 M) | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | (8.34) X | ||||
| Target Price | 12.0 | ||||
| Number Of Employees | 10 | ||||
| Beta | 0.22 | ||||
| Market Capitalization | 3.53 M | ||||
| Total Asset | 3.22 M | ||||
| Retained Earnings | (107.61 M) | ||||
| Working Capital | 1.14 M | ||||
| Current Asset | 9.59 M | ||||
| Current Liabilities | 937 K | ||||
| Net Asset | 3.22 M |
About Bio Path Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Path Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Path using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Path Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:Check out Bio Path Piotroski F Score and Bio Path Altman Z Score analysis. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.34) | Return On Assets (1.40) | Return On Equity (3.66) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.